Optimizing Health-System Resources to Deliver System Wide Antimicrobial Stewardship

Brad Laible, PharmD, BCPS-AQ ID
Jawad Nazir, MD, FACP
Jamie Grosdidier, PharmD
Disclosure

- The program chair and presenters for this continuing education activity have reported no relevant financial relationships.
Learning Objectives:

- Discuss initial approaches when starting a health-system antimicrobial stewardship program (ASP)

- Give examples of how existing personnel/resources can be used to enhance patient-level stewardship across the health-system

- Describe how a system-level ASP can impact an individual facility with limited antimicrobial stewardship resources
Antimicrobial Expertise Poll

- Do you have Infectious Disease Physician(s) and Pharmacist(s) at your practice site?
  - Both ID Physician and Pharmacist
  - ID physician only
  - ID pharmacist only
  - No ID Physician or Pharmacist
1. Install the app from pollev.com/app
2. Make sure you are in Slide Show mode

Still not working? Get help at pollev.com/app/help or Open poll in your web browser
Avera Health Antimicrobial Stewardship Program (ASP)

- Scope:
  - Review antimicrobials for formulary / antimicrobial restrictions
  - Review/approval of infectious disease-related order sets and treatment algorithms
  - Adjustment/conversion policies (e.g. renal, IV to PO)
  - Review of antibiogram and antimicrobial utilization data
  - Provide education to providers and other staff
  - Conduct the “ASP Daily Call”
Antimicrobial Formulary

- **Beta-lactams**
  - PCN, aminopenicillins, Piperacillin-tazobactam
  - Cephalosporins (limited)
  - Meropenem, Ertapenem

- **Fluoroquinolones**
  - Levofloxacin, ciprofloxacin

- **Aminoglycosides**

- **Antifungals**
  - Fluconazole
  - Micafungin
  - Voriconazole, Posaconazole, Isavuconazole*
  - Amphotericin B products*

- **MRSA+/- VRE active**
  - Vancomycin
  - Trimethoprim-sulfam.
  - Clindamycin
  - Daptomycin*
  - Linezolid*
  - Tigecycline*
  - Ceftaroline*
  - Telavancin*

- **Others***
  - Fidaxomicin
  - Fosfomycin
  - Colistin

*ID restricted at MCK
# Infection-Related Order Sets: Avera System

## Pneumonia - CAP ICU

**Severe Sepsis Quality Measure**
- Checkmark: Severe Sepsis Quality Measure (NQM)
- Date: Today Now

**Medications**
- Initiate antibiotics within 6 hours of presentation to hospital
- 2007 IDSA Concensus Guidelines for Management of CAP

**Recommended INITIAL Therapy - Select BOTH Ceftriaxone AND Azithromycin**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosage Details</th>
<th>Bottle Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftriaxone 2 Gm/D5w (Rocephin 2 Gm Ivpb)</td>
<td>250 ML IV daily 250 MLS/HR</td>
<td>Give first dose stat</td>
</tr>
<tr>
<td>Azithromycin 500 Mg/D5w (Zithromax 500mg Ivpb)</td>
<td>250 ML IV daily 250 MLS/HR</td>
<td>Give first dose stat</td>
</tr>
</tbody>
</table>

**If Beta-Lactam Allergy - Choose Both**

- Avera Health recommends reserving quinolone therapy for patients with documented beta-lactam allergy.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosage Details</th>
<th>Bottle Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>LevoFLOXacin 750 MG/D5W (LEVAQUIN 750 MG IVPB)</td>
<td>150 ML IV daily 100 MLS/HR</td>
<td>Give first dose stat</td>
</tr>
<tr>
<td>Aztreonam 2 Gm D5w 50ml (Azactam) 50 ML</td>
<td>IV 8h 100 MLS/HR</td>
<td>Give first dose stat</td>
</tr>
</tbody>
</table>

**If patient has risk for infection with Pseudomonas aeruginosa, please consult**

<table>
<thead>
<tr>
<th>Consult Physician (CONS)</th>
<th>Reason for Consult Pneumonia</th>
<th>Consulting Specialty or Group: Infectious Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Today Now</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Other Order Sets

- **Standard Order Sets**
- **Addl Order Sets**
- **Anesthesia**
- **Behavior Health**
- **Cardiology**
- **Critical Care**
- **ED Meds**
- **Emergency Dept**
- **Medical**
- **Neonatology**
- **Nephrology**

### Order Sets:

- Pneumonia - CAP ICU
- Pneumonia - CAP Med Surg
- Pneumonia - HCAP
- Prednisone Taper Short Set
- Radiocont Induced Nephropa
- Reclast (Zoledronic acid) 5 m
- Remicade (Infliximab)
- Rheum IV Cyclophosphamide
- Rheumatology Orders
- Rheumatology RIUXimab Orders
- Sepsis Fluid Bolus 50-54.9 k
- Short Stay Unit Chest Pain
- Short Stay Unit Syncope
- Skin and Soft-Tissue Infection
- Syncope Short Set
- Thoracentesis - Pre and Post
- Urinary Tract Infection
- Wound Ostomy Care Eval & -
### Antimicrobial Renal Dosing Policy: Avera System

**Avera Health System Antimicrobial Dosing Guideline for Patients with Impaired Renal Function**

**Avera ID Subcommittee**

**Update March 2016**

**Weight Key:** TBW = Total Body Weight, IBW = Ideal Body Weight

**Note:** This is a renal dosing guideline only. This guideline is not intended to guide agent selection. Any listing of possible indications is not all inclusive, and clinical judgment is necessary when selecting the base dose for the suspected infection. Discussion with the antimicrobial stewardship team/ID consult may be warranted to ensure selection of the appropriate base dose and subsequent renal adjustments.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Route</th>
<th>Typical Base Doses</th>
<th>CrCl (mL/min)</th>
<th>HD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aceclovir</td>
<td>IV</td>
<td>Use lesser of TBW vs IBW</td>
<td>25-50: 100% of dose q12h</td>
<td>Dose after CrCl &gt;10, dose after HD on dialysis days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 – 10 mg/kg q8h</td>
<td>10-24: 100% of dose q24h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 10: 50% of dose q24h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin</td>
<td>IV</td>
<td>2 gm q4h</td>
<td>If base dose 2 gm q4h</td>
<td>Dose after CrCl &lt; 10, give one of the doses after HD on dialysis days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Suggested for CNS infections, Endocarditis, Osteomyelitis)</td>
<td>30-50: 2 gm q8h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 – 29: 2 gm q8h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt; 10: 2 gm q12h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2gm q8h</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1gm q6h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin-Sulbactam</td>
<td>IV</td>
<td>3 gm q6h</td>
<td>If base dose 3 gm q6h</td>
<td>Dose after CrCl &lt; 10, dose after HD on dialysis days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30-50: 3 gm q8h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 – 29: 3 gm q12h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt; 10: 3 gm q24h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.5 gm q8h</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Annual Antibiogram: Avera McKennan

### AVERA MCKENNAN ANTIMICROBIAL SUSCEPTIBILITY TESTING 2015

#### GRAM POSITIVE

<table>
<thead>
<tr>
<th>Organism</th>
<th>Total</th>
<th>TMP/S</th>
<th>GENT</th>
<th>SYN</th>
<th>CLINDA</th>
<th>ERYTH</th>
<th>CIPRO</th>
<th>LEVO</th>
<th>FD</th>
<th>OXA</th>
<th>LIN</th>
<th>PEN-G</th>
<th>VANCO</th>
<th>CFT (nongpering)</th>
<th>CFT (staphylococcal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staph aureus</td>
<td>787</td>
<td>96%</td>
<td>100%</td>
<td>80%</td>
<td>21%</td>
<td>71%</td>
<td>99%</td>
<td>100%</td>
<td></td>
<td>100%</td>
<td>100%</td>
<td>18%</td>
<td>100%</td>
<td>84%</td>
<td>96%</td>
</tr>
<tr>
<td>MRSA</td>
<td>390</td>
<td>100%</td>
<td>100%</td>
<td>66%</td>
<td>12%</td>
<td>0%</td>
<td>0%</td>
<td>100%</td>
<td></td>
<td>100%</td>
<td>0%</td>
<td>100%</td>
<td></td>
<td>96%</td>
<td></td>
</tr>
<tr>
<td>Staph epidermidis</td>
<td>582</td>
<td>86%</td>
<td>100%</td>
<td>52%</td>
<td>11%</td>
<td>5%</td>
<td>100%</td>
<td>37%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>0%</td>
<td>100%</td>
<td>96%</td>
<td>96%</td>
</tr>
<tr>
<td>Staph hominis</td>
<td>74</td>
<td>74%</td>
<td>100%</td>
<td>63%</td>
<td>31%</td>
<td>12%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>27%</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>Enterococcus faecalis 39</td>
<td>76%</td>
<td>1%</td>
<td>100%</td>
<td>87%</td>
<td>12%</td>
<td>83%</td>
<td>94%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Enterococcus faecium VRE</td>
<td>76%</td>
<td>1%</td>
<td>100%</td>
<td>87%</td>
<td>12%</td>
<td>83%</td>
<td>94%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Enterococcus faecium VRE</td>
<td>76%</td>
<td>1%</td>
<td>100%</td>
<td>87%</td>
<td>12%</td>
<td>83%</td>
<td>94%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Enterococcus faecium VRE</td>
<td>76%</td>
<td>1%</td>
<td>100%</td>
<td>87%</td>
<td>12%</td>
<td>83%</td>
<td>94%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Streptococcus pneumonia</td>
<td>76%</td>
<td>1%</td>
<td>100%</td>
<td>87%</td>
<td>12%</td>
<td>83%</td>
<td>94%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Streptococcus agalactiae</td>
<td>76%</td>
<td>1%</td>
<td>100%</td>
<td>87%</td>
<td>12%</td>
<td>83%</td>
<td>94%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>25%</td>
<td></td>
</tr>
</tbody>
</table>

#### GRAM NEGATIVE

<table>
<thead>
<tr>
<th>Organism</th>
<th>Total</th>
<th>AMP</th>
<th>AMP/SUL</th>
<th>CEFAZO</th>
<th>CEFTRI</th>
<th>GENT</th>
<th>CPE</th>
<th>CIPRO</th>
<th>LEVO</th>
<th>PIP/TAZO</th>
<th>TOBRA</th>
<th>TMP/S</th>
<th>MEM</th>
<th>CEFTAZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citrobacter freundii</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Escherichia coli ESBL</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Klebsiella oxytoca</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Morganella morganii</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Proteus mirabilis</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
<tr>
<td>Serratia marcescens</td>
<td>2794</td>
<td>86%</td>
<td>100%</td>
<td>92%</td>
<td>1%</td>
<td>0%</td>
<td>99%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td>99%</td>
</tr>
</tbody>
</table>

**Annotations:**
- # in green: ≤5% increase in susceptibility
- # in red: ≥5% decrease in susceptibility
- # in green & highlighted yellow: ≥25% increase in susceptibility
- # in red & highlighted yellow: ≥25% decrease in susceptibility

**Legend:**
- AMP = Ampicillin
- AMP/SUL = Ampicillin/ Sulbactam
- CEFAZO = Cefazolin
- CEFTRI = Ceftriaxone
- CFT = Cefotaxime
- CFTP = Cefotaxime
- CLINDA = Clindamycin
- CPE = Cefepime
- ERYTH = Erythromycin
- FDX = Nitrofurantoin
- GENT SYN = Gentamicin synergy
- LEVO = Levofloxacin
- LIN = Linezolid
- MEM = Meropenem
- OXA = Oxacillin (equals Methicillin)
- PEN-G = Penicillin-G
- PIP/TAZO = Piperacillin/Tazobactam
- SYN = Synercid
- TOBRA = Tobramycin
- TMP/S = Trimethoprim/Sulfamethoxazole
- VANCO = Vancomycin
- TE = Teicoplanin

**Footnote:**
- 95% increase in susceptibility:
- 95% decrease in susceptibility:
- 95% increase in susceptibility:
### Fluoroquinolone Susceptibility Trends

<table>
<thead>
<tr>
<th></th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E. coli</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>87</td>
<td>79</td>
<td>80</td>
<td>80</td>
<td>77</td>
<td>75</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>75</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P. aeruginosa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>75</td>
<td>72</td>
<td>75</td>
<td><strong>57</strong></td>
<td>70</td>
<td><strong>64</strong></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>70</td>
</tr>
</tbody>
</table>
Levofloxacin Days of Therapy/1000 Patient Days
Avera McKennan Inpatient Use

2011 Antibiogram Education
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E. coli</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>87</td>
<td>79</td>
<td>80</td>
<td>80</td>
<td>77</td>
<td>75</td>
<td>82</td>
<td>84</td>
<td>85</td>
<td>85</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>75</td>
<td>82</td>
<td>84</td>
<td>85</td>
<td>85</td>
</tr>
<tr>
<td><strong>P. aeruginosa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>75</td>
<td>72</td>
<td>75</td>
<td>57</td>
<td>70</td>
<td>64</td>
<td>64</td>
<td>79</td>
<td>80</td>
<td>79</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>70</td>
<td>70</td>
<td>82</td>
<td>82</td>
<td>82</td>
</tr>
</tbody>
</table>
Which of the following should commonly be implemented in the early stages as a good foundation for a health-system ASP?

A. Develop a system antimicrobial formulary
B. Develop antimicrobial-related order sets and treatment pathways based on antibiogram review
C. Implement renal dosing and IV to PO conversion policies
D. Identify a common problem
E. All of the above
Your poll will show here

1. Install the app from pollev.com/app
2. Make sure you are in Slide Show mode

Still not working? Get help at pollev.com/app/help
or
Open poll in your web browser
Technology Poll

Do you already use or have access to screen-sharing conference call technology at your facility?

- Yes
- No
- Don’t know
Your poll will show here

1. Install the app from pollev.com/app
2. Make sure you are in Slide Show mode

Still not working? Get help at pollev.com/app/help
or
Open poll in your web browser
ASP Daily Call: Avera System

- Conference call utilizing screen sharing
- Conducted Monday – Friday, 11 AM
- ID physicians and pharmacists review patient cases for potential stewardship interventions
  - Cultures/labs/diagnostics/chart notes reviewed
  - Broad spectrum antimicrobial use is targeted
    - Piperacillin-tazobactam, cefepime, meropenem, fluoroquinolones
    - Vancomycin
- Pharmacists relay the ASP recommendations to providers
Screen Sharing

Run Date: 05/17/16
Run Time: 1544
Avera Health Laboratory
Laboratory Specimen Report

PATIENT: TEST, PHARMACY
ACCT: MK0023999642
AGE/SEX: 156/F
REG DR: Other, Dr
REG: 09/22/15
REG #: MK0023999642

SPEC #: MK16M0039675R
COLL: 05/17/16-1528 STATUS: COMP -
RECO: 05/17/16-1528 SUEN DR: Other, Dr
ENTR: 05/17/16-1529 OTHR DR:

SP DESC:
ORDERED: WOUND

Procedure | Result | Verified | Site
---|---|---|---
WOUND CULTURE | Final | 05/17/16-1543 | MCK

<table>
<thead>
<tr>
<th>Organism 1</th>
<th>ESCHERICHIA COLI</th>
<th>Light growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organism 2</td>
<td>STREP AGALACTIAE GROUP B</td>
<td>Light growth</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ESC COLI</th>
<th></th>
<th>ST AGALACT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M.I.C.</td>
<td>RX</td>
<td>ABN</td>
<td>M.I.C.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim/Sulfamethoxazole</td>
<td>0.5</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin</td>
<td>128</td>
<td>S</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Ampicillin/Sulbactam</td>
<td>32</td>
<td>R</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>4</td>
<td>S</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Cettrazicline</td>
<td>1</td>
<td>S</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>1</td>
<td>S</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Cepefime</td>
<td>2</td>
<td>S</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0.25</td>
<td>S</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>0.25</td>
<td>S</td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>8</td>
<td>R</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Meropenem</td>
<td>0.01</td>
<td>S</td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>Pencillin</td>
<td>0.12</td>
<td>S</td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>0.12</td>
<td>S</td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>8</td>
<td>R</td>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>1</td>
<td>S</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Piperacillin/Tazobactam</td>
<td>4</td>
<td>S</td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>0.12</td>
<td>S</td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Linezolid</td>
<td>S</td>
<td>S</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

MCK - Avera McKennan Laboratory
1325 S. Cliff, Sioux Falls, SD 57105
Pharmacy Presentation of Patient to Infectious Disease (ID) Physician During ASP Rounds

This is a (age) year old male/female admitted for (chief complaint). Discuss suspected infection, for example: We are suspecting urinary tract infection. Discuss current antimicrobial therapy, for example: The patient is currently receiving Zosyn, day 3. Discuss culture results if applicable, for example: Urine culture from (date) is positive for *E. coli*. Discuss resistance of organisms identified (if applicable), for example: The *E. coli* is only resistant to ampicillin. Discuss potential recommendation (if known), for example: I thought perhaps we could suggest de-escalation to ceftriaxone or an oral agent. I wanted to get your thoughts.

Pharmacy Presentation of ASP Recommendations to Provider:

First-Time Recommendation to a Specific Provider:

For the first time you make an ASP recommendation to a provider, we suggest you start with the following statement:

I am not sure if you are aware Avera Health has developed an Antimicrobial Stewardship Program in hopes of improving antimicrobial use and limiting resistance across the system. As part of this effort, we have the opportunity to review patient cases with an ID physician through a conference call each day.

Recommendation Presentation:

Your patient (name) was discussed at ASP rounds. Based on review of the patient’s chart, including documentation and culture results (if applicable), our antimicrobial stewardship physician (Name) is suggesting (recommendation). For example: Dr. Nazir suggests changing Zosyn to ceftriaxone (or an oral agent that could be specified) for this patient to complete 7 days of therapy.
Date of Recommendation

Month  Day  Year
Sep  20  2016

Facility: *

- Avera McKennan
- Avera St. Mary’s
- Avera St. Luke’s
- Avera Queen of Peace
- Avera Marshall
- Avera Sacred Heart
- Other

Suspected Infection Type By Site (Select all that apply) *

- Urinary
- Respiratory
- Skin / Soft Tissue
- Bone / Joint
Interventions By Avera Facility
October 16, 2015 to August 16, 2016

Avera Queen of Peace: 32%
Avera McKennan: 22%
Avera St. Luke’s: 26%
Avera St. Mary’s: 9%
Avera Sacred Heart: 9%
Other Facility: 2%

n = 354
Type of Recommendation

n = 495

- Stop Antimicrobials (s): 22%
- De-escalation: 23%
- Change to adequate coverage: 5%
- Dosing adjustment or IV to PO: 16%
- Facilitate Discharge: 17%
- Other: 17%

Stop Antimicrobials (s)  De-escalation
Change to adequate coverage  Dosing adjustment or IV to PO
Facilitate Discharge  Other
Antimicrobials Involved

- Vancomycin: 33%
- Piperacillin-tazobactam: 22%
- Cefepime: 18%
- Levofloxacin: 11%
- Carbapenem: 6%
- Other: 10%
Recommendation Accepted & Implemented
October 16, 2015 to August 16, 2016

Yes 91%

No 9%
n = 354
How much time does this really take?

- July 1st – August 31st, 2016
- Averaged 1 ID physician and 5 Pharmacists per call
- 90 patients presented / 33 call days (2.7 patients per call)
- 23 minutes per call
Sharing of Knowledge

- Examples of Educational Topics Discussed
  - The Joint Commission ASP standard
  - New HAP/VAP guidelines
  - Fluoroquinolone resistance trends locally and nationally
  - Clostridium bacteremia treatment
  - Evaluation of Pseudomonal susceptibility trends locally
  - Enterobacter and drugs of choice
  - Asymptomatic bacterurua treatment
  - Cefazolin and MSSA susceptibility testing
  - HCAP in nursing home patients
- Literature commonly distributed for further education
Is it possible to use existing personnel to implement a health-system ASP?

A. YES
B. NO
Your poll will show here

1. Install the app from pollev.com/app
2. Make sure you are in Slide Show mode

Still not working? Get help at pollev.com/app/help or Open poll in your web browser
Avera Queen of Peace Hospital

- 120 Bed Regional Medical Center
  - Emergency
  - Medical
  - Surgical
  - Intensive Care
  - Maternal Care
  - Pediatrics
  - Cancer Center
  - Telemedicine, Rehab Services, Outpatient Therapy

- No formal Antimicrobial Stewardship Team
Queen of Peace Hospital
Where we started – Antimicrobial monitoring

- Microbiology/Pharmacy interface
- Pneumonia diagnosis review
- Appropriate Fluoroquinolone utilization
- Duplicate coverage monitoring
- Aminoglycoside/Vancomycin Protocols
- IV to PO conversion
Getting started

- Administration commitment
- Pharmacy buy in
- Physician education/recruitment
- Implementation
Daily Antimicrobial Stewardship Call

- Identify Patients to present
- Presentation of Patient to Infectious Disease (Daily call)
- Follow-up with Prescribing Physician
- Documentation
Tips/Lessons learned

1. Start Slow
2. Be Selective – Start with wins
3. Provide a service
Stewardship – not Police Presence
Pharmacist Survey – All Responses

If you have presented a patient case (or had one presented on your behalf), do you feel the advice given during the Daily ASP Call has made your recommendations more effective?

- Strongly agree
- Agree
- Neutral
- Disagree / Strongly Disagree

I have not presented a patient case (or...)

n = 41
Pharmacist Survey – Non-MCK Responses

If you have presented a patient case (or had one presented on your behalf), do you feel the advice given during the Daily ASP Call has made your recommendations more effective?

- Strongly agree
- Agree
- Neutral
- Disagree / Strongly Disagree

I have not presented a patient case (or...)

n = 17
Pharmacist Survey – Non-MCK Responses

Are you likely to present a patient case (or have one presented on your behalf) during the Daily ASP Call in the future?

- Strongly agree: [Bar Graph]
- Agree: [Bar Graph]
- Neutral: [Bar Graph]
- Disagree / Strongly Disagree: [Bar Graph]

Antimicrobial review is not a routine part of my daily activities

n = 17
Pharmacist Survey – Non-MCK Responses

Additional comments of note:

- “It is a great resource and I feel has made a significant impact.”
- “It is great to get advice from specialist on a subject where many providers struggle. The process is expedient and professional. Thank you for all the support.”
- “I appreciate this call being available to our hospital.”
- “Even when not presenting a patient, the information/advice given is very helpful for future reference.”
- “This tool is greatly appreciated by the entire patient care team... pharmacists, physicians and nursing. It provides an extra means of best practice clinical care for our patients.”
- “Hospitalists are very receptive to the recommendations provided by the ID physicians and receiving this information from the pharmacist that participated during the ASP call. Hospitalist service often contacts pharmacy to have a patient case discussed during the daily call.”
Provider Feedback

- 91% acceptance rate, but how do the individual physicians feel about it...

“Together with my colleagues, I am extremely elated and happy to endorse the Antibiotic Stewardship Program in cooperation with The Avera Infectious Disease Specialists. Not only that this adds to the highest quality of patient care but it also augments my medical education and to the students under my preceptorship.”

“This is a valuable service. We are able to get expert consultation on appropriate antibiotic use for our patients. This is a cost-savings as well as an appropriate use of antibiotics. We should continue this service.”
Case Presentation #1

- 90 yr old female admitted with cellulitis of right leg
- Initiated on Nafcillin 2 gm IV every 6 hr plus Vancomycin 800 mg IV every 24 hr

Initial SCr = 1.01
Case Presentation #2

- 82 year old, end-stage COPD
  End of life vs possible early pneumonia
- Started on Ceftriaxone + Azithromycin
- Condition deteriorates over 2 days
Antibiotic Stewardship at Queen of Peace Hospital

- Optimizing antibiotic utilization to improve outcomes
- Service – not policing prescribers
Final thoughts

- It’s not always going to be black and white
- Listen to the patient
Can a health-system ASP make a substantial impact on an individual facility?

A. YES
B. NO
Your poll will show here

1. Install the app from pollev.com/app
2. Make sure you are in Slide Show mode

Still not working? Get help at pollev.com/app/help
or
Open poll in your web browser
Key Takeaways

- Set yourself up for success by developing an antimicrobial formulary, order sets/treatment pathways, renal dosing/IV to PO policies before tackling multidisciplinary prospective audit & feedback.

- Existing resources can be used to deliver effective antimicrobial stewardship, even at a health-system level.

- System-wide stewardship programs can positively impact individual facilities through education and support rather than policing antimicrobial use.